Literature DB >> 34045312

p53 Frameshift Mutations Couple Loss-of-Function with Unique Neomorphic Activities.

David R Tong1, Wen Zhou1, Chen Katz1, Kausik Regunath1, Divya Venkatesh1, Chinyere Ihuegbu1, James J Manfredi2, Oleg Laptenko3, Carol Prives3.   

Abstract

p53 mutations that result in loss of transcriptional activity are commonly found in numerous types of cancer. While the majority of these are missense mutations that map within the central DNA-binding domain, truncations and/or frameshift mutations can also occur due to various nucleotide substitutions, insertions, or deletions. These changes result in mRNAs containing premature stop codons that are translated into a diverse group of C-terminally truncated proteins. Here we characterized three p53 frameshift mutant proteins expressed from the endogenous TP53 locus in U2OS osteosarcoma and HCT116 colorectal cancer cell lines. These mutants retain intact DNA-binding domains but display altered oligomerization properties. Despite their abnormally high expression levels, they are mostly transcriptionally inactive and unable to initiate a stimuli-induced transcriptional program characteristic of wild-type p53. However, one of these variant p53 proteins, I332fs*14, which resembles naturally expressed TAp53 isoforms β and γ, retains some residual antiproliferative activity and can induce cellular senescence in HCT116 cells. Cells expressing this mutant also display decreased motility in migration assays. Hence, this p53 variant exhibits a combination of loss-of-gain and gain-of-function characteristics, distinguishing it from both wild type p53 and p53 loss. IMPLICATIONS: p53 frameshift mutants display a mixture of residual antiproliferative and neomorphic functions that may be differentially exploited for targeted therapy. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34045312      PMCID: PMC8419077          DOI: 10.1158/1541-7786.MCR-20-0691

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

1.  p53 isoforms can regulate p53 transcriptional activity.

Authors:  Jean-Christophe Bourdon; Kenneth Fernandes; Fiona Murray-Zmijewski; Geng Liu; Alexandra Diot; Dimitris P Xirodimas; Mark K Saville; David P Lane
Journal:  Genes Dev       Date:  2005-08-30       Impact factor: 11.361

2.  Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response.

Authors:  V Marcel; K Fernandes; O Terrier; D P Lane; J-C Bourdon
Journal:  Cell Death Differ       Date:  2014-06-13       Impact factor: 15.828

3.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Authors:  Steffen Boettcher; Peter G Miller; Rohan Sharma; Marie McConkey; Matthew Leventhal; Andrei V Krivtsov; Andrew O Giacomelli; Waihay Wong; Jesi Kim; Sherry Chao; Kari J Kurppa; Xiaoping Yang; Kirsten Milenkowic; Federica Piccioni; David E Root; Frank G Rücker; Yael Flamand; Donna Neuberg; R Coleman Lindsley; Pasi A Jänne; William C Hahn; Tyler Jacks; Hartmut Döhner; Scott A Armstrong; Benjamin L Ebert
Journal:  Science       Date:  2019-08-09       Impact factor: 47.728

4.  Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.

Authors:  Noa Rivlin; Ran Brosh; Moshe Oren; Varda Rotter
Journal:  Genes Cancer       Date:  2011-04

5.  Lysines in the tetramerization domain of p53 selectively modulate G1 arrest.

Authors:  Rachel Beckerman; Kathryn Yoh; Melissa Mattia-Sansobrino; Andrew Zupnick; Oleg Laptenko; Orit Karni-Schmidt; Jinwoo Ahn; In-Ja Byeon; Susan Keezer; Carol Prives
Journal:  Cell Cycle       Date:  2016-05-21       Impact factor: 4.534

Review 6.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

Review 7.  Mechanisms of transcriptional regulation by p53.

Authors:  Kelly D Sullivan; Matthew D Galbraith; Zdenek Andrysik; Joaquin M Espinosa
Journal:  Cell Death Differ       Date:  2017-11-10       Impact factor: 15.828

Review 8.  Two faces of p53: aging and tumor suppression.

Authors:  Francis Rodier; Judith Campisi; Dipa Bhaumik
Journal:  Nucleic Acids Res       Date:  2007-10-16       Impact factor: 16.971

9.  Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks.

Authors:  Martin Fischer; Patrick Grossmann; Megha Padi; James A DeCaprio
Journal:  Nucleic Acids Res       Date:  2016-06-08       Impact factor: 16.971

10.  Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers.

Authors:  Ana Maria Low-Calle; Joshua H Choe; Chen Katz; Oleg Laptenko; David Tong; Jazmine-Saskya N Joseph-Chowdhury; Francesca Garofalo; Yan Zhu; Assaf Friedler; Carol Prives
Journal:  Genes Dev       Date:  2018-03-16       Impact factor: 11.361

View more
  1 in total

1.  Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.

Authors:  George K Annor; Nour Elshabassy; Devon Lundine; Don-Gerard Conde; Gu Xiao; Viola Ellison; Jill Bargonetti
Journal:  Front Cell Dev Biol       Date:  2021-11-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.